Johnson & Johnson (NYSE:JNJ) Shares Sold by Papp L Roy & Associates

Defense World · Mar 26, 2023 20:30

Papp L Roy & Associates lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 112,873 shares of the company's stock after selling 3,908 shares during the quarter. Johnson & Johnson makes up 2.8% of Papp L Roy & Associates' holdings, making the stock its 8th biggest holding. Papp L Roy & Associates' holdings in Johnson & Johnson were worth $19,939,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. DORCHESTER WEALTH MANAGEMENT Co raised its position in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company's stock valued at $14,975,000 after buying an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P lifted its position in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company's stock valued at $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. boosted its holdings in Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company's stock worth $3,244,000 after purchasing an additional 1,475 shares during the last quarter. Equitable Holdings Inc. grew its position in Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company's stock worth $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd increased its stake in Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company's stock valued at $152,488,000 after buying an additional 20,528 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Get Johnson & Johnson alerts:

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. Citigroup lifted their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a "buy" rating in a research note on Monday, December 12th. SVB Leerink lowered their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a research report on Friday, January 20th. Atlantic Securities increased their target price on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a "neutral" rating in a research report on Wednesday, January 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. Finally, StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a "strong-buy" rating for the company. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $174.73.

Insider Buying and Selling at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Stock Up 1.0 %

NYSE:JNJ opened at $152.65 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The firm's 50-day moving average price is $159.76 and its 200-day moving average price is $167.55. The company has a market capitalization of $397.54 billion, a PE ratio of 22.65, a P/E/G ratio of 2.60 and a beta of 0.54. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts' consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter last year, the firm earned $2.13 earnings per share. The business's revenue for the quarter was down 4.4% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson's dividend payout ratio (DPR) is 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.